

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

Efficacy and Safety of Aliskiren Combination Therapy: A Protocol for An Umbrella Review

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-043807
Article Type:	Protocol
Date Submitted by the Author:	14-Aug-2020
Complete List of Authors:	Shen, Jiantong; Huzhou University, medicine & nursing school; Huzhou Central Hospital, Feng, Wenming ; Huzhou first people hospital; The First Affiliated Hospital of Huzhou University Wang, Yike; Huzhou University, medicine & nursing school; Zhejiang University School of Medicine Second Affiliated Hospital Zhao, Qiyuan; Huzhou University, Flavorta, BILLONG Laura; Huzhou University, medicine & nursing school Lu, Jingya; Huzhou University
Keywords:	Hypertension < CARDIOLOGY, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, VASCULAR MEDICINE
	·





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

relievon

2 3		
4	1	Title:
5	1	
6	2	Efference of Alistica Constinction Theorem A Dustrial for An United 11 Design
7	2	Efficacy and Safety of Aliskiren Combination Therapy: A Protocol for An Umbrella Review
8		
9	3	Corresponding Author:
10		
11	4	LiontonaShan
12	4	JiantongShen;
13		
14 15	5	Institution: School of Medicine, Huzhou University; Huzhou Central Hospital
16		
17	6	Mailing address: No. 759, East 2nd Road, Huzhou, China (313000)
18	0	Walning address. No. 757, East 2nd Road, Hužnou, China (515000)
19		
20	7	e-mail: <u>sjiantong@163.com</u>
21		
22	8	Tel: +86-18057201236
23	0	
24	_	
25	9	Co-authors:
26		
27	10	JiantongShen; School of Medicine, Huzhou University, Huzhou Central Hospital, 759
28		
29	11	
30	11	ErHuan Road, Huzhou, 313000, Zhejiang, PR China.
31 32		
33	12	Wenming Fen; The First Affiliated Hospital of Huzhou University, 158 Back of Square Road,
34		
35	13	Huzhou, 313000, Zhejiang, PR China.
36	15	Tiuzhou, 515000, Zhejiang, FK Clinia.
37		
38	14	YikeWang; School of Nursing, Huzhou University, 759 ErHuan Road, Huzhou, 313000,
39		
40	15	Zhejiang, PR China.
41	15	Enejiang, i K ennia.
42		
43	16	Qiyuan Zhao; School of Nursing, Huzhou University, 759 ErHuan Road, Huzhou, 313000,
44		
45	17	Zhejiang, PR China.
46 47	1,	
47 49	10	
48 49	18	BILLONG Laura Flavorta; School of Nursing, Huzhou University, 759 ErHuan Road,
5 0		
51	19	Huzhou, 313000, Zhejiang, PR China.
52		
53	20	Linear Les School a Straning Hacker Hairconite 750 Fallers Deed Hacker 212000
54	20	Jingya Lu; School of Nursing, Huzhou University, 759 ErHuan Road, Huzhou, 313000,
55		
56	21	Zhejiang, PR China.
57		
58	าา	Word count: 2870
59	22	
60		
		1

24

ABSTRACT

Introduction

1

BMJ Open

1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
20 21	
22	
23 24	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
40 47	
47	
49 50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

25	Efficacy of aliskiren combination therapy with other antihypertensive has been evaluated in
26	the treatment of patients with hypertension in recent systematic reviews. However, most
27	previous reviews only focused on one single health outcome or one setting, none of them
28	made a full summary that assessed the impact of aliskiren combination treatment
29	comprehensively. As such, this umbrella review is aimed to synthesize the evidences on
30	efficacy, safety and tolerability of aliskiren-based therapy for hypertension and related
31	comorbid patients.
32	Methods and analysis
33	A comprehensive search of PubMed, EMBASE, Cochrane Library, CNKI published from
34	inception to August 2020 will be conducted. The selected articles are systematic reviews
35	which evaluated efficacy, safety and tolerability of aliskiren combination therapy. Two
36	reviewers will screen eligible articles, extract data and evaluate quality independently. Any
37	disputes will be resolved by discussion or the arbitration of a third person. The quality of
38	reporting evidence will be assessed using the AMSTAR2 tool. We will take a mixed-methods
39	approach to synthesizing the review literatures, reporting summary of findings tables and
40	iteratively mapping the results.
41	Ethics and dissemination

42 Ethical approval is not required for the study, as we would only collect data from available
43 published materials. This umbrella review will be also submitted to a peer-reviewed journal
44 for publication after completion.

Trial Registration

<text> Our study has been registered in PROSPERO (CRD42020192131)

Keywords: Aliskiren; combination therapy; clinical outcome

1 2			
- 3 4 5	48	Sti	rengths and limitations of this study
6 7	49	•	This will be the first study that systematically summarizes the effectiveness, safety and
8 9 10	50		tolerability of aliskiren combination therapy.
11 12 13	51	٠	When sufficient data are available, we will compare clinical outcomes of different
14 15	52		aliskiren combination therapies.
16 17 18	53	•	If the included reviews in our study are not of high quality, we will re-analyze each
19 20 21	54		outcome using the random effects model.
22 23	55	•	The methodological quality of the eligible reviews will be evaluated using AMSTAR2 for
24 25 26	56		assessing risk of bias.
27 28 29	57	•	The results of this umbrella review are an asset to patients, clinicians and researchers,
30 31	58		help them to better acknowledge the scientific value of aliskien combined use.
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	59		4

60	INTRODUCTION
----	---------------------

Aliskiren is the first in a new class of oral, non-peptide, low molecular weight direct renin inhibitor (DRI). It has been approved by the US Food and Drug Administration (FDA) for the management of hypertension in2007^[1]. As studies revealed, aliskirenis effective in controlling blood pressure as monotherapy^[2,3]. Furthermore, researchers found that aliskiren could provide more anti-hypertension efficacy when combined with other kinds of blood pressure medicines ^[4-8]. An increasing number of clinical trials and systematic reviews have assessed the anti-hypertension efficacy and tolerability of aliskiren combination therapies ^[4,9,10]. However, there has yet to be a comprehensive evidence map that summarizes the wide array of health benefits and safety of aliskiren combination treatments. As noted above, existing systematic reviews on aliskiren combination treatments focused on single health outcomes, and most reviews evaluated only one type of combination treatment rather than exploring the multiple combination treatments. In addition, due to the diversity in settings, types and outcomes of aliskiren combination treatments, the quality of these reviews were varied. Umbrella reviews can systematically appraise evidence in the published literature by evaluating meta-analyses of multiple combination treatment on multiple outcomes^[11].We would perform an umbrella review of systematic reviews to holistically evaluate and summarize existing systematic reviews that assess the efficacy, safety and tolerability of aliskiren combination therapy.

METHODS

80 Protocol development

Page 7 of 16

1

BMJ Open

23	
4	
5	
6	
7	
8	
9	
10	
10	
11	
12	
13	
14	
15	
16	
17	
17	
18	
19	
20	
5 6 7 8 9 10 11 12 13 14 15 16 17 19 20 21 22 23 24 25 26 27 28 29 30	
22	
23	
24	
27	
25	
26	
27	
28	
29	
30	
31	
21	
32 33	
34 35	
35	
36	
36 37 38	
20	
39	
40	
41	
42	
43	
44	
45	
46	
40 47	
48	
49	
50	
51	
52	
53	
55 54	
54 55	
56	
57	
58	
59	

60

81 This umbrella review protocol follows the Joanna Briggs Institute Methodology for Umbrella 82 Reviews ^[12]. This protocol was also developed to align with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) 2015 statement ^[13] and has 83 been registered with the PROSPERO database for systematic reviews (CRD42020192131). 84 85 **Eligibility criteria** 86 We used the population, intervention, comparator, outcomes and study design structure in 87 formulating the scope of this umbrella review. 88 Population: This umbrella review will include systematic reviews that include hypertension 89 patients and related comorbid populations. 90 Intervention: This umbrella review will include systematic reviews that focus on aliskiren 91 combination with other anti-hypertension medicine, such as ARBs, ACEIs, HCTZs. 92 Comparators: Aliskiren monotherapy or aliskiren combined with another medicine. 93 Outcomes 94 We will assess the following outcomes: The primary efficacy outcomes were cardiovascular 95 outcomes such as mortality rate, the composite of death and major adverse events, the 96 incidence of stroke and myocardial infarction. Secondary efficacy outcomes were rates of therapeutic response and BP control, reduction from baseline to the end of treatment in mean 97 98 clinical SBP (Δ mSBP) and DBP (Δ mDBP). The safety of drug was assessed by incidence of 99 some adverse events such as hyperkalaemia, acute kidney injury. The tolerability of the drug 100 was assessed by considering overall rates of any adverse events and withdrawal from a study 101 due to adverse events. Reviews with any of the above outcomes will be included. 102 **Type of studies:** Systematic reviews, meta-analyses or pooled analyses

Page 8 of 16

BMJ Open

The reviews that were out of date will be excluded. Meta-analyses that did not provide

specific study data (number of incident events, number of study population, follow-up period, relative risks and 95% confidence intervals (CI)) and in which the missing data was not retrievable from the original studies will be excluded. **Search Strategy** We will search the following databases from inception of databases to August 2020: Pubmed, Embase, Cochrane Library and CNKI. Additionally, we will manually search all reference lists of the included studies to identify additional reviews of relevance. We developed this search strategy using keywords, MeSH (Medical Subject Headings) terms and text words, which will be searched in combination (aliskiren OR direct renin inhibitor OR renin-angiotensin inhibition OR spp100 OR takturna) AND (systematic review OR meta-analysis OR pooled analysis). We will modify the database-specific controlled vocabulary and key terms to suit the above mentioned databases. Study screening Electronic search results will be down loaded into Endnote software, and duplicates will be removed automatically and manually based on an exact match of the title, date, author and result. Two reviewers will independently screen titles and abstracts of retrieved articles according to the inclusion and exclusion criteria. When the reviewers cannot decide the eligibility of a study through title or abstract screening, full-texts will be screened. Disagreements between reviewers will be resolved using consensus, and by a third reviewer if necessary. The outline of the study selection procedure will be shown in a flow chart

(Figure 1).

Page 9 of 16

1 2

2 3		
5 4 5	125	Data Extraction
6 7	126	Standardized abstraction forms will be established in Microsoft EXCEL, and the data from
8 9 10	127	each eligible systematic review will be extracted by two reviewers independently.
11 12 13	128	Ambiguities related to data extraction will be resolved by discussion or by a third reviewer if
14 15	129	the reviewers are unable to achieve consensus. The following information will be extracted:
16 17 18	130	characteristics of included reviews (e.g. first author, publication year, number and type of
19 20	131	studies included in each review, total sample size), population (disease conditions),
21 22 23	132	intervention and control (medicine of intervention or control, sample size of each group and
24 25	133	details of treatment, follow-up period) and outcomes (name and definition of outcome,
26 27 28	134	summary effect size and its related 95% CI and the number of participants included in the
29 30 31	135	outcome assessment). When the data are only provided through plots, we will use Ycasd to
32 33	136	determine the effect size and its 95% CI [14]. We will contact the corresponding authors to ask
34 35 36	137	for data, when necessary data were not provided in the article.
37 38	138	Assessment of methodological quality of included reviews
39 40 41	139	The quality of the included studies will be appraised by using the Assessment of Multiple
42 43	140	Systematic Reviews 2 tool (AMSTAR2, an updated version of AMSTAR), which is updated
44 45 46 47 48 49 50 51	141	to allow for both randomized and observational studies. Unlike its predecessor, AMSTAR 2
	142	has the capacity to identify critical weaknesses that reduce confidence in the findings of a
	143	review ^[15] . AMSTAR 2 consists of 16 items with the following response options: Yes, Partial
52 53 54	144	Yes and No. Two reviewers will independently rate the quality of each systematic review as
55 56 57 58 59 60	145	high, moderate, low and critically low based on the overall score of the AMSTAR2. Any

1 2	
-	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
40 47	
47 48	
40 49	
49 50	
50 51	
52	
52 53	
55 54	
54 55	
55 56	
57 50	
58	
59	
60	

1

disagreements between reviewers will be resolved among themselves through discussion andby a third reviewer if being unable to achieve consensus.

148 Data synthesis and statistical analysis

149 Statistical analysis will be conducted using RevManV.5.3 software and StataV.14.0 software. 150 In our analysis, when possible, we will stratify the comparisons into several groups according 151 to the characteristics of our targeted population. We will divide patients into three groups: 152 simple hypertension patients, patients with hypertension and diabetes; and patients who are suffering from hypertension, diabetes and nephropathy or albuminuria at the same time. 153 154 When evaluating antihypertensive effects, we will divide patients into three groups: young 155 patients (<50years), early elderly patients (50-70years), elderly patients (>70years). 156 For each outcome, if the random model was already used, we will extract the pooled 157 effect sizes of included systematic review. If not, we will extract original data and reanalyze 158 them with the random effect methods to get the pooled effect size and its related 95% CI. We 159 will also estimate the 95% prediction interval (95% PI) for the summary estimate based on 160 the random-effect model, to represent the range in which the effect estimates of future studies 161 will lie. The Q and I² test statistics will be calculated to determine the degree of heterogeneity. 162 For the Q statistic, p<0.05 will be considered significant. We will classify the degree of 163 heterogeneity into substantial heterogeneity ($I^2 > 50\%$) and considerable heterogeneity 164 (I²>75%).We will conduct a Bayesian network meta-analysis to estimate relative combination 165 therapy effects based on a synthesis of direct and indirect evidence. 166 Where no quantitative pooling of effect sizes was reported or where outcomes were reported descriptively by single studies, we will provide these results by using standardized 167

2		
3 4 5	168	language indicating direction of effect and statistical significance.
6 7 8	169	If an outcome is examined at least 3 articles, we will use Egger's test (conducted using
9 10	170	StataV.14.0) to evaluate if the reporting bias exists. Values of p<0.1 will be interpreted as
11 12 13	171	statistically significant ^[16] .
14 15	172	All included systematic reviews and meta-analyses will be screened for over lapping of
16 17 18	173	included original studies. We will explore this through the use of The Cochrane Handbook's
19 20 21	174	template for mapping individual primary studies contained within included systematic
22 23	175	reviews [17]. If reviews are reporting the same outcomes from the same study, we will
24 25 26	176	highlight this overlap. To assess the degree of overlap, we will calculate the corrected
27 28	177	covered area (CCA) ^[18] . A CCA score of 0-5 indicates slight overlap, 6-10 moderate, 11-15
29 30 31	178	high and >15 very high. We will consider overlap when interpreting results of the overview.
32 33 34	179	Patient and public involvement
35 36	180	Patients and/or the public were involved in the design, or conduct, or reporting, or
37 38 39	181	dissemination plans of this research. The results of this work will be disseminated to the
40 41	182	public via conferences, publications and presentations.
42 43 44	183	DISCUSSION
45 46	184	Aliskiren is an orally administered, direct renin inhibitor approved in numerous
47 48 49	185	countries, including the US and the EU for the management of hypertension. The clinical
50 51 52	186	efficacy and tolerability of aliskiren-based therapy in hypertension have been previously
53 54	187	reviewed by many systematic reviews, while the evidence about aliskiren combination
55 56 57	188	therapy has not been appraised holistically. Umbrella review is a review of systematic
58 59	189	reviews and meta-analyses, which is viewed as one of the four next-generation
60		

190 meta-analyses^[19].

For this umbrella review, we will (1) identify and synthesize existing review and meta-analysis studies on aliskiren combination therapies; (2) critically evaluate the available evidence both narrative and quantitative; and (3) identify the most prominent aliskiren combination treatment used to manage hypertension. We will use qualitative methods and quantitative methods to synthesizing the review literatures. We plan to evaluate the credibility of included evidences. We will create the summary of findings tables and report a summary of findings from all included reviews based on data synthesis, presenting a comprehensive overview of what is known in the literatures about the efficacy, safety and tolerability of different aliskiren combination therapies. This is the first umbrella review about aliskiren combination therapy. Summarizing these evidences will be an asset to clinicians and researchers aiming to improve the scientific of aliskien combine use. Anticipated limitations of our study are the heterogeneity and quality of the included reviews. To address the limitations, we will reanalyze each outcome using the random effects model and evaluate the quality of included studies. Furthermore, these two factors will be carefully considered when interpreting the results. Another limitation of this overview will be the potential for study overlap across reviews. Considering this potential bias, we will examine and report on any overlap in the overview. Despite anticipated limitations, this umbrella review will be conducted using the most systematic procedures available at this time. Adhering to these guidelines helps ensure that we produce a high-quality umbrella review, which will be a useful and trustworthy resource for interested parties.

2		
3 4 5	212	Ethics and dissemination
6 7 8	213	Ethical approval is not required for the study, as we only collected data from available
9 10	214	materials. This umbrella review will be also submitted to a peer-reviewed journal for
11 12 13	215	publication.
14 15	216	Authors' contributors
16 17 18	217	Jiantong Shen and Wenming Fen carried on the conception and construction of this protocol.
19 20 21	218	Yike Wang developed the search strategy. Qiyuan Zhao and Jingya Lu compared and found
22 23	219	the best tools for assessing possible bias and evaluating quality of included reviews. Jiantong
24 25 26	220	Shen wrote the protocol. BILLONG Laura Flavorta added grammar editing and conceptual
27 28	221	clarification. All authors read and approved of the final manuscript.
29 30 31	222	Funding statement
32 33 34	223	This work was supported by the Department of Education of Zhejiang Province, China [Grant
35 36	224	numbers Y201635273] and Chinese Academic Degree and Postgraduate Education Society
37 38 39	225	Medical Science Working Committee [Grant numbers B3-YX20190302-18]
40 41	226	Competing interests
42 43 44	227	Competing interests None declared
45 46 47	228	Patient and public involvement
48 49	229	No patients and public are involved in developing plans for project and implementation of
50 51 52	230	this study. None of them are asked to advise on interpretation of results. The results will be
53 54	231	disseminated to the general population through public presentations by the authors.
55 56 57	232	
58 59 60		
50		12


233	REFERENCES
234	1. Duggan ST, Chwieduk CM, Curran MP. Aliskiren: a review of its use as monotherapy and
235	as combination therapy in the management of hypertension. Drugs 2010; 70:2011-49.
236	2. Zhao QY, Shen JT, Lu JY, et al. Clinical efficacy, safety and tolerability of Aliskiren
237	Monotherapy (AM): an umbrella review of systematic reviews. BMC Cardiovasc Disord
238	2020; 20:179.
239	3. Musini VM, Lawrence KA, Fortin PM, et al. Blood pressure lowering efficacy of renin
240	inhibitors for primary hypertension. Cochrane Database Syst Rev 2017; 4:CD007066.
241	4. Liu Y, Chen K, Kou X, et al. Aliskiren and Amlodipine in the Management of Essential
242	Hypertension: Meta-Analysis of Randomized Controlled Trials. PLoS ONE 2013; 8: e70111
243	5. Miyoshi T, Murakami T, Sakuragi S, et al. Comparable effect of aliskiren or a diuretic
244	added on an angiotensin II receptor blocker on augmentation index in hypertension: a
245	multicentre, prospective, randomised study. Open Heart 2017;4:e000591.
246	6. Abdel Kawy HS. Aliskiren and valsartan in combination is a promising therapy for
247	hypertensive renal injury in rats. Clin Exp Hypertens 2018; 40:560-8.
248	7. Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and
249	valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370:
250	221-9.
251	8. Littlejohn TW 3rd, Trenkwalder P, Hollanders G, et al. Long-term safety, tolerability and
252	efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension.
253	Curr Med Res Opin 2009; 25:951-9.

2		
3 4 5	254	9. Liu Y, Yan R, Song A, et al. Aliskiren/amlodipine vs. aliskiren/hydrochlorothiazide in
6 7 8	255	hypertension: indirect meta-analysis of trials comparing the two combinations vs.
9 10	256	monotherapy. Am J Hypertens 2014; 27:268-78.
11 12 13	257	10. Zhang JT, Chen KP, Guan T, et al. Effect of aliskiren on cardiovascular outcomes in
14 15	258	patients with prehypertension: a meta-analysis of randomized controlled trials. Drug Des
16 17 18	259	Devel Ther 2015;9:1963-71.
19 20	260	11. Aromataris E, Fernandez R, Godfrey CM, et al. Summarizing systematic reviews:
21 22 23	261	methodological development, conduct and reporting of an umbrella review approach. Int J
24 25 26	262	Evid Based Healthc 2015; 13:132-40.
27 28	263	12. Aromataris E, Fernandez RS, Godfrey C, et al. Methodology for JBI Umbrella Reviews.
29 30 31	264	The Joanna Briggs Institute; 2014.
32 33	265	13. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review
34 35 36	266	and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
37 38	267	14. Gross A, Schirm S, Scholz M. Ycasd - a tool for capturing and scaling data from
39 40 41	268	graphical representations. BMC Bioinformatics 2014; 15:219.
42 43 44	269	15. Shea BJ, Reeves BC, Wells G, et al. AMSTAR2: a critical appraisal tool for systematic
45 46	270	reviews that include randomised or non-randomised studies of healthcare interventions, or
47 48 49	271	both. <i>BMJ</i> 2017; 358:1-8.
50 51	272	16. Poole R, Kennedy OJ, Roderick P, et al. Coffee consumption and health: umbrella review
52 53 54	273	of meta-analyses of multiple health outcomes. BMJ 2017; 359:j5024-18.
55 56		
57		
58 59		
59 60		

2 3	
5 4 5	27
6 7	27
8 9 10	27
11 12	27
13 14 15	27
16 17	27
18 19 20	28
21 22 23	
23 24 25	
26 27 28	
20 29 30	
31 32	
33 34 35	
36 37	
38 39	
40 41 42	
43 44	
45 46	
47 48 49	
50 51	
52 53	
54 55 56	
56 57 58	
59 60	

- 75 Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from
 - 76 www.training.cochrane.org/handbook.
 - 77 18. Pieper D, Antoine S-L, Mathes T, et al. Systematic review finds overlapping reviews
- 78 were not mentioned in every other overview. J Clin Epidemiol 2014; 67:368-75.
- , rste. 79 19. Ioannidis J. Next-generation systematic reviews: prospective meta-analysis,

30 individual-level data, networks and umbrella reviews. Br J Sports Med 2017; 51:1456-8.



BMJ Open

Efficacy and Safety of Aliskiren Combination Therapy: A Protocol for An Umbrella Review

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-043807.R1
Article Type:	Protocol
Date Submitted by the Author:	27-Nov-2020
Complete List of Authors:	Shen, Jiantong; Huzhou University, medicine & nursing school; Huzhou Central Hospital, Feng, Wenming ; Huzhou first people hospital; The First Affiliated Hospital of Huzhou University Wang, Yike; Huzhou University, medicine & nursing school; Zhejiang University School of Medicine Second Affiliated Hospital Zhao, Qiyuan; Huzhou University, Flavorta, BILLONG Laura; Huzhou University, medicine & nursing school Lu, Jingya; Huzhou University
Primary Subject Heading :	Cardiovascular medicine
Secondary Subject Heading:	Evidence based practice
Keywords:	Hypertension < CARDIOLOGY, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, VASCULAR MEDICINE





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

relievont

- 3 ⊿	1	Title:
4 5	1	
6 7 8	2	Efficacy and Safety of Aliskiren Combination Therapy: A Protocol for An Umbrella Review
8 9 10	3	Corresponding Author:
11 12 13	4	JiantongShen;
14 15	5	Institution: School of Medicine, Huzhou University; Huzhou Central Hospital
16 17 18	6	Mailing address: No. 759, East 2nd Road, Huzhou, China (313000)
19 20 21	7	e-mail: <u>sjiantong@163.com</u>
22 23	8	Tel: +86-18057201236
24 25 26	9	Wenming Feng;
27 28	10	Institution: The First Affiliated Hospital of Huzhou University
29 30 31	11	Mailing address: 158 Back of Square Road, Huzhou, 313000, Zhejiang, PR China.
32 33	12	e-mail: <u>d_fengwm@sina.com</u>
34 35 36	13	Tel: +86-05722321239
37 38 39	14	Co-authors:
40 41	15	JiantongShen; School of Medicine, Huzhou University, Huzhou Central Hospital, 759
42 43 44	16	ErHuan Road, Huzhou, 313000, Zhejiang, PR China.
45 46 47	17	Wenming Feng; The First Affiliated Hospital of Huzhou University, 158 Back of Square
47 48 49	18	Road, Huzhou, 313000, Zhejiang, PR China.
50 51 52	19	YikeWang; School of Nursing, Huzhou University, 759 ErHuan Road, Huzhou, 313000,
53 54	20	Zhejiang, PR China.
55 56 57	21	Qiyuan Zhao; School of Nursing, Huzhou University, 759 ErHuan Road, Huzhou, 313000,
58 59 60	22	Zhejiang, PR China.

1 ว

2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
17	
13 14 15 16 17	
16	
17	
18	
10	
19 20	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
20	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
57	

60

- 23 BILLONG Laura Flavorta; School of Nursing, Huzhou University, 759 ErHuan Road,
- 24 Huzhou, 313000, Zhejiang, PR China.
- 25 Jingya Lu; School of Nursing, Huzhou University, 759 ErHuan Road, Huzhou, 313000,
- 26 Zhejiang, PR China.
- 27 Word count: 2870

For beet terien only

28 ABSTRACT

29 Introduction

Efficacy of aliskiren combination therapy with other antihypertensive has been evaluated in the treatment of patients with hypertension in recent systematic reviews. However, most previous reviews only focused on one single health outcome or one setting, none of them made a full summary that assessed the impact of aliskiren combination treatment comprehensively. As such, this umbrella review based on systematic reviews and meta-analyses is aimed to synthesize the evidences on efficacy, safety and tolerability of aliskiren-based therapy for hypertension and related comorbid patients. **Methods and analysis** A comprehensive search of PubMed, EMBASE, Cochrane Library, CNKI published from inception to August 2020 will be conducted. The selected articles are systematic reviews which evaluated efficacy, safety and tolerability of aliskiren combination therapy. Two reviewers will screen eligible articles, extract data and evaluate quality independently. Any disputes will be resolved by discussion or the arbitration of a third person. The quality of reporting evidence will be assessed using the AMSTAR2 tool. We will take a mixed-methods approach to synthesizing the review literatures, reporting summary of findings tables and iteratively mapping the results. **Ethics and dissemination**

47 Ethical approval is not required for the study, as we would only collect data from available
48 published materials. This umbrella review will be also submitted to a peer-reviewed journal
49 for publication after completion.

1 2		
- 3 4 5	50	Trial Registration
6 7	51	Our study has been registered in PROSPERO (CRD42020192131)
8 9 10	52	Keywords: Aliskiren; combination therapy; clinical outcome
11 12 13		
14 15 16		
17 18		
19 20 21		
22 23 24		
25 26		
27 28 29		
30 31 32		
33 34 35		
36 37		
38 39 40		
41 42 43		
44 45 46		
47 48		
49 50 51		
52 53 54		
55 56 57		
58 59		
60		4

3 4 5	53	Sti	rengths and limitations of this study
6 7 8	54	•	This will be the first study that systematically summarizes the effectiveness, safety and
9 10	55		tolerability of aliskiren combination therapy.
11 12 13	56	•	When sufficient data are available, we will compare clinical outcomes of different
14 15	57		aliskiren combination therapies.
16 17 18	58	•	If the included reviews in our study are not of high quality, we will re-analyze each
19 20 21	59		outcome using the random effects model.
22 23	60	•	Anticipated limitations of our study are the heterogeneity and quality of the included
24 25 26	61		reviews. Another limitation of this overview will be the potential for study overlap across
27 28 29	62		reviews.
30 31	63	•	The results of this umbrella review are an asset to patients, clinicians and researchers,
32 33 34	64		help them to better acknowledge the scientific value of aliskien combined use.
35 36 37 38	65		
39 40 41 42			
43 44 45			
46 47			
48 49 50			
50 51 52			
53			
54 55			
56 57			
58 59			
60			
			5

INTRODUCTION

BMJ Open

67	Aliskiren is the first in a new class of oral, non-peptide, low molecular weight direct renin
68	inhibitor (DRI). It has been approved by the US Food and Drug Administration (FDA) for the
69	management of hypertension in 2007 ^[1] . As studies revealed, aliskiren was effective in
70	controlling blood pressure as monotherapy ^[2,3] . Furthermore, researchers found that aliskiren
71	could provide more anti-hypertension efficacy when combined with other kinds of blood
72	pressure medicines [4-8]. An increasing number of clinical trials and systematic reviews have
73	assessed the anti-hypertension efficacy and tolerability of aliskiren combination therapies
74	^[4,9,10] . However, there has yet to be a comprehensive evidence map that summarizes the wide
75	array of health benefits and safety of aliskiren combination treatments. As noted above,
76	existing systematic reviews on aliskiren combination treatments focused on single health
77	outcomes, and most reviews evaluated only one type of combination treatment rather than
78	exploring the multiple combination treatments. In addition, due to the diversity in settings,
79	types and outcomes of aliskiren combination treatments, the quality of these reviews were
80	varied. Umbrella reviews can systematically appraise evidence in the published literature by
81	evaluating meta-analyses of multiple combination treatment on multiple outcomes ^[11] .We
82	would perform an umbrella review of systematic reviews to holistically evaluate and
83	summarize existing systematic reviews that assess the efficacy, safety and tolerability of
84	aliskiren combination therapy.
85	METHODS

86 Protocol development

2 3 4 5 6 7 8 9 10 11 2 13 14 15 16 17 18 19 20 12 22 3 24 5 26 7 28 29 30 13 22 33 34 55 67 8 9 10 11 21 31 41 51 61 71 81 92 21 22 32 42 52 27 28 29 30 13 22 33 34 53 63 73 83 94 41 42 43 44 55 15 55 55 55 55 55 55 55 55 55 55 55	1	
4 5 6 7 8 9 10 11 2 13 14 15 16 17 18 19 20 21 22 32 4 25 26 27 28 29 30 13 22 33 34 35 36 37 38 39 40 14 24 34 44 5 46 47 48 49 50 51 52 53 54 55 56 57 58 59	2	
5 6 7 8 9 10 11 2 13 14 15 16 17 18 19 20 21 22 32 4 25 6 27 28 29 30 132 33 435 36 37 8 9 40 41 42 34 45 46 47 48 9 50 51 52 53 54 55 55 55 55 55 55 55		
$egin{array}{cccccccccccccccccccccccccccccccccccc$		
$\begin{array}{c} 7\\ 8\\ 9\\ 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 12\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 34\\ 45\\ 46\\ 47\\ 48\\ 9\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 55\\ 55\\ 55\\ 55\\ 55\\ 55\\ 55\\ 55$		
9 10 11 12 13 14 15 16 7 18 19 20 21 22 32 4 25 26 27 28 29 30 132 33 34 35 36 37 38 9 40 41 42 34 45 46 47 48 9 50 51 52 53 54 55 55 55 55 55 59	6	
9 10 11 12 13 14 15 16 7 18 19 20 21 22 32 4 25 26 27 28 29 30 132 33 34 35 36 37 38 9 40 41 42 34 45 46 47 48 9 50 51 52 53 54 55 55 55 55 55 59	7	
$\begin{array}{c} 10\\ 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 03\\ 13\\ 23\\ 34\\ 35\\ 36\\ 37\\ 38\\ 940\\ 41\\ 42\\ 34\\ 45\\ 46\\ 47\\ 48\\ 950\\ 51\\ 52\\ 53\\ 54\\ 55\\ 55\\ 55\\ 55\\ 55\\ 55\\ 55\\ 55\\ 55$		
$\begin{array}{c} 11\\ 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 23\\ 34\\ 35\\ 36\\ 37\\ 38\\ 940\\ 41\\ 42\\ 43\\ 44\\ 56\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\\ 58\\ 59\end{array}$		
$\begin{array}{c} 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 23\\ 34\\ 35\\ 36\\ 37\\ 38\\ 9\\ 40\\ 41\\ 42\\ 43\\ 44\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 7\\ 58\\ 59\end{array}$		
$\begin{array}{c} 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 56\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\\ 58\\ 59\end{array}$		
$\begin{array}{c} 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\\ 58\\ 59\end{array}$		
$\begin{array}{c} 15 \\ 16 \\ 17 \\ 18 \\ 19 \\ 20 \\ 21 \\ 22 \\ 23 \\ 24 \\ 25 \\ 26 \\ 27 \\ 28 \\ 29 \\ 30 \\ 31 \\ 32 \\ 33 \\ 34 \\ 35 \\ 36 \\ 37 \\ 38 \\ 9 \\ 41 \\ 42 \\ 43 \\ 44 \\ 56 \\ 51 \\ 52 \\ 53 \\ 54 \\ 55 \\ 57 \\ 58 \\ 59 \end{array}$		
$\begin{array}{c} 16 \\ 17 \\ 18 \\ 19 \\ 20 \\ 21 \\ 22 \\ 23 \\ 24 \\ 25 \\ 26 \\ 27 \\ 28 \\ 29 \\ 30 \\ 31 \\ 32 \\ 33 \\ 34 \\ 35 \\ 36 \\ 37 \\ 38 \\ 940 \\ 41 \\ 42 \\ 44 \\ 45 \\ 46 \\ 47 \\ 48 \\ 49 \\ 50 \\ 51 \\ 52 \\ 53 \\ 54 \\ 55 \\ 57 \\ 58 \\ 59 \end{array}$		
$\begin{array}{c} 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 56\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\\ 58\\ 59\\ \end{array}$		
$\begin{array}{c} 18\\ 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\\ 58\\ 59\end{array}$		
$\begin{array}{c} 19\\ 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 56\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\\ 58\\ 59\\ \end{array}$		
$\begin{array}{c} 20\\ 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 45\\ 46\\ 47\\ 48\\ 49\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\\ 58\\ 59\end{array}$		
$\begin{array}{c} 21\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 45\\ 46\\ 47\\ 48\\ 49\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\\ 58\\ 59\end{array}$		
$\begin{array}{c} 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 45\\ 46\\ 47\\ 48\\ 49\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\\ 58\\ 59\end{array}$		
23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 50 51 52 53 54 55 56 57 58 59		
$\begin{array}{c} 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\\ 58\\ 59\end{array}$		
25 26 27 28 29 30 31 32 33 4 35 36 37 38 39 40 41 42 43 44 50 51 52 53 54 55 56 57 58 59		
26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 50 51 52 53 54 55 56 57 58 59		
$\begin{array}{c} 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 45\\ 46\\ 47\\ 48\\ 49\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\\ 57\\ 58\\ 59\\ \end{array}$		
28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59		
29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59		
30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 950 51 52 53 54 55 56 57 58		
 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 		
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59		
 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 		
 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 		
 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 		
 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 		
 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 		
 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 		
 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 		
40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59		
41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59		
42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59		
43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59		
44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59	43	
45 46 47 48 49 50 51 52 53 54 55 56 57 58 59		
46 47 48 49 50 51 52 53 54 55 56 57 58 59		
47 48 49 50 51 52 53 54 55 56 57 58 59		
48 49 50 51 52 53 54 55 56 57 58 59		
49 50 51 52 53 54 55 56 57 58 59		
50 51 52 53 54 55 56 57 58 59		
51 52 53 54 55 56 57 58 59		
53 54 55 56 57 58 59	51	
54 55 56 57 58 59		
55 56 57 58 59		
56 57 58 59		
57 58 59		
58 59		
59		
60		
	60	

1

87 This umbrella review protocol follows the Joanna Briggs Institute Methodology for Umbrella Reviews ^[12]. This protocol was also reported align with the Preferred Reporting Items for 88 Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) 2015 statement ^[13] and has 89 been registered with the PROSPERO database for systematic reviews (CRD42020192131). 90 91 **Eligibility criteria** 92 We used the population, intervention, comparator, outcomes and study design structure in 93 formulating the scope of this umbrella review. 94 **Population:** This umbrella review will include systematic reviews that include hypertension 95 patients and related comorbidity populations. Hypertension define as blood pressure $\geq 140/90$ 96 mmHg for office measurement. 97 **Intervention:** This umbrella review will include systematic reviews that focus on aliskiren 98 combination with other anti-hypertension medicine, such as ARBs, ACEIs, HCTZs. 99 **Comparators:** Aliskiren monotherapy or aliskiren combined with another medicine. 100 **Outcomes** We will assess the following outcomes: The primary efficacy outcomes were cardiovascular 101 102 outcomes such as mortality rate, the composite of death and major adverse events, the 103 incidence of stroke and myocardial infarction, any acute coronary syndrome. Secondary 104 efficacy outcomes were rates of therapeutic response and BP control (audit standard of < 105 140/90 mmHg for office measurement), reduction from baseline to the end of treatment in 106 mean clinical SBP ($\Delta mSBP$) and DBP ($\Delta mDBP$). We will use clinic blood pressure. The 107 safety of drug was assessed by incidence of some adverse events such as hyperkalaemia, 108 acute kidney injury, angioedema and postural hypotension. The tolerability of the drug was 109 assessed by considering overall rates of any adverse events and withdrawal from a study due

1 2	
2 3 4 5 6 7 8 9	
6 7	
8 9 10	
10 11 12 13 14 15 16 17 18 19	
14 15	
16 17 18	
19 20	
20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37	
24 25 26	
27 28	
29 30 31	
32 33	
34 35 36	
37 38 39	
40 41	
42 43 44	
45 46	
47 48 49	
50 51 52	
53 54	
55 56 57	
58 59	
60	

110	to adverse events. Reviews with any of the above outcomes will be included. We will also
111	consider cost- effectiveness results such as incremental cost- effectiveness ratios, average
112	cost-effectiveness ratio, benefit-cost ratio and unit costs.
113	Type of studies: Systematic reviews, meta-analyses or pooled analyses
114	The reviews that were out of date will be excluded. Meta-analyses that did not provide
115	specific study data (number of incident events, number of study population, follow-up period,
116	relative risks and 95% confidence intervals (CI)) and in which the missing data was not
117	retrievable from the original studies will be excluded.
118	Search Strategy
119	We will search the following databases from inception of databases to August 2020: Pubmed,
120	Embase, Cochrane Library and CNKI. Additionally, we will manually search all reference
121	lists of the included studies to identify additional reviews of relevance.
122	We developed this search strategy using keywords, MeSH (Medical Subject Headings) terms
123	and text words, which will be searched in combination (aliskiren OR direct renin inhibitor
124	OR renin-angiotensin inhibition OR spp100 OR takturna OR Rasilez) AND (systematic
125	review OR meta-analysis OR pooled analysis) (see Supplementary 1). We will modify the
126	database-specific controlled vocabulary and key terms to suit the above mentioned databases.
127	Study screening
128	Electronic search results will be down loaded into Endnote software, and duplicates will be
129	removed automatically and manually based on an exact match of the title, date, author and
130	result. Two reviewers will independently screen titles and abstracts of retrieved articles
131	according to the inclusion and exclusion criteria. When the reviewers cannot decide the

eligibility of a study through title or abstract screening, full-texts will be screened. Disagreements between reviewers will be resolved using consensus, and by a third reviewer if necessary. The outline of the study selection procedure will be shown in a flow chart (Figure 1). **Data Extraction** Standardized abstraction forms will be established in Microsoft EXCEL, and the data from each eligible systematic review will be extracted by two reviewers independently. Ambiguities related to data extraction will be resolved by discussion or by a third reviewer if the reviewers are unable to achieve consensus. The following information will be extracted: characteristics of included reviews (e.g. first author, publication year, number and type of studies included in each review, total sample size), population (disease conditions), intervention and control (medicine of intervention or control, sample size of each group and details of treatment, dosing of treatment, follow-up period) and outcomes (name and definition of outcome, summary effect size and its related 95% CI and the number of participants included in the outcome assessment). When the data are only provided through

Assessment of methodological quality of included reviews

The quality of the included studies will be appraised by using the Assessment of Multiple Systematic Reviews 2 tool (AMSTAR2, an updated version of AMSTAR), which is updated to allow for both randomized and observational studies. Unlike its predecessor, AMSTAR 2 has the capacity to identify critical weaknesses that reduce confidence in the findings of a

plots, we will use Ycasd to determine the effect size and its 95% CI^[14]. We will contact the

corresponding authors to ask for data, when necessary data were not provided in the article.

BMJ Open

2		
3		
4		
5		
6		
7		
/		
8		
9		
	0	
1	1	
1	2	
1		
1	4	
1	5	
	6	
1	7	
	/	
	8	
	9	
	0	
	1	
2	2	
2	3	
	4	
2		
	6	
2		
	8	
	9	
	0	
3	1	
3	2	
3	3	
	4	
3		
	5 6	
3		
	8	
3	9	
4	0	
4	1	
4		
4	3	
	4	
•	5	
	5 6	
4		
	8	
4		
	0	
5		
5		
5		
	4	
	4 5	
5	6	
5		
5	8	
5	9	

60

review^[15]. AMSTAR 2 consists of 16 items with the following response options: Yes, Partial
Yes and No. Two reviewers will independently rate the quality of each systematic review as
high, moderate, low and critically low based on the overall score of the AMSTAR2. Any
disagreements between reviewers will be resolved among themselves through discussion and
by a third reviewer if being unable to achieve consensus.

159 Data synthesis and statistical analysis

160 Statistical analysis will be conducted using RevManV.5.3 software and StataV.14.0 software. In our analysis, when possible, we will stratify the comparisons into several groups according 161 162 to the characteristics of our targeted population. We will divide patients into three groups: 163 simple hypertension patients, patients with hypertension and diabetes; and patients who are suffering from hypertension, diabetes and nephropathy or albuminuria (an eGFR < 60164 165 mL/min/1.73 m2 or The Kidney Disease Improving Global Outcomes (KDIGO) GFR stages 166 3 to 5) at the same time. In order to be consistent with changes in the classification and 167 diagnostic criteria for diabetes over the years, the diagnosis should be established using the standard criteria valid at the time of the trial commencing (for example ADA 2003; ADA 168 169 2008; WHO 1998). Ideally, the diagnostic criteria should have been described. We will use 170 the trial authors' definition of diabetes mellitus if necessary. We plan to subject diagnostic 171 criteria to a sensitivity analysis. When evaluating antihypertensive effects, we will divide patients into three groups: young patients (<50years), early elderly patients (50-70years), 172 173 elderly patients (>70years).

For each outcome, if the random model was already used, we will extract the pooled
effect sizes of included systematic review. If not, we will extract original data and reanalyze

176	them with the random effect methods to get the pooled effect size and its related 95% CI. We				
177	will also estimate the 95% prediction interval (95% PI) for the summary estimate based on				
178	the random-effect model, to represent the range in which the effect estimates of future studies				
179	will lie. The Q and I ² test statistics will be calculated to determine the degree of heterogeneity.				
180	For the Q statistic, p<0.05 will be considered significant. We will classify the degree of				
181	heterogeneity into substantial heterogeneity (I ² >50%) and considerable heterogeneity				
182	(I ² >75%). We will conduct a Bayesian network meta-analysis to estimate relative				
183	combination therapy effects based on a synthesis of direct and indirect evidence.				
184	Where no quantitative pooling of effect sizes was reported or where outcomes were				
185	reported descriptively by single studies, we will provide these results by using standardized				
186	language indicating direction of effect and statistical significance.				
187	If an outcome is examined at least 3 articles, we will use Egger's test (conducted using				
188	StataV.14.0) to evaluate if the reporting bias exists. Values of p<0.1 will be interpreted as				
189	statistically significant ^[16] .				
190	All included systematic reviews and meta-analyses will be screened for over lapping of				
191	included original studies. We will explore this through the use of The Cochrane Handbook's				
192	template for mapping individual primary studies contained within included systematic				
193	reviews [17]. If reviews are reporting the same outcomes from the same study, we will				
194	highlight this overlap. To assess the degree of overlap, we will calculate the corrected				
195	covered area (CCA) ^[18] . A CCA score of 0-5 indicates slight overlap, 6-10 moderate, 11-15				
196	high and >15 very high. We will consider overlap and do sensitivity analyses when				
197	interpreting results of the overview.				

BMJ Open

2	
3	
4	
5	
6	
0	
7	
8	
9	
10	
11	
10	
12	
13	
14	
15	
16 17	
18	
18 19	
20	
21	
22	
23	
24	
25	
26 27	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
40 47	
48	
49	
50	
51	
52	
53	
55	
54	
55	
56	
57	
58	
59	
60	

219

198 **Patient and public involvement**

199 No patients and public are involved in developing plans for project and implementation of 200 this study. None of them are asked to advise on interpretation of results. The results will be 201 disseminated to the general population through public presentations by the authors.

202 **DISCUSSION**

Aliskiren is an orally administered, direct renin inhibitor approved in numerous countries, including the US and the EU for the management of hypertension. The clinical efficacy and tolerability of aliskiren-based therapy in hypertension have been previously reviewed by many systematic reviews, while the evidence about aliskiren combination therapy has not been appraised holistically. Umbrella review is a review of systematic reviews and meta-analyses, which is viewed as one of the four next-generation meta-analyses [19].

For this umbrella review, we will (1) identify and synthesize existing review and 210 211 meta-analysis studies on aliskiren combination therapies; (2) critically evaluate the available evidence both narrative and quantitative; and (3) identify the most prominent aliskiren 212 213 combination treatment used to manage hypertension. We will use qualitative methods and 214 quantitative methods to synthesizing the review literatures. We plan to evaluate the 215 credibility of included evidences. We will create the summary of findings tables and report a 216 summary of findings from all included reviews based on data synthesis, presenting a 217 comprehensive overview of what is known in the literatures about the efficacy, safety and 218 tolerability of different aliskiren combination therapies.

12

This is the first umbrella review about aliskiren combination therapy. Summarizing


these evidences will be an asset to clinicians and researchers aiming to improve the scientific of aliskien combine use. Anticipated limitations of our study are the heterogeneity and quality of the included reviews. To address the limitations, we will reanalyze each outcome using the random effects model and evaluate the quality of included studies. Furthermore, these two factors will be carefully considered when interpreting the results. Another limitation of this overview will be the potential for study overlap across reviews. Considering this potential bias, we will examine and report on any overlap in the overview. Despite anticipated limitations, this umbrella review will be conducted using the most systematic procedures available at this time. Adhering to these guidelines helps ensure that we produce a high-quality umbrella review, which will be a useful and trustworthy resource for interested parties. **Ethics and dissemination** Ethical approval is not required for the study, as we only collected data from available materials. This umbrella review will be also submitted to a peer-reviewed journal for publication. **Authors' contributors** Jiantong Shen and Wenming Feng carried on the conception and construction of this protocol. Yike Wang developed the search strategy. Qiyuan Zhao and Jingya Lu compared and found the best tools for assessing possible bias and evaluating quality of included reviews. Jiantong Shen wrote the protocol. BILLONG Laura Flavorta added grammar editing and conceptual clarification. All authors read and approved of the final manuscript.

2 3 4 5	241	Funding statement
6 7	242	This work was supported by the Department of Education of Zhejiang Province, China [Grant
8 9 10 11 12 13 14 15 16	243	numbers Y201635273], Chinese Academic Degree and Postgraduate Education Society
	244	Medical Science Working Committee [Grant numbers B3-YX20190302-18], and the
	245	National Social Science Fund of China[Grant numbers 20BTQ042].
17 18	246	Competing interests
19 20 21 22 23 24 25 26 27 28 29	247	None declared REFERENCES
	248	1. Duggan ST, Chwieduk CM, Curran MP. Aliskiren: a review of its use as monotherapy and
	249	as combination therapy in the management of hypertension. <i>Drugs</i> 2010; 70:2011-49.
	250	2. Zhao QY, Shen JT, Lu JY, et al. Clinical efficacy, safety and tolerability of Aliskiren
30 31 32	251	Monotherapy (AM): an umbrella review of systematic reviews. BMC Cardiovasc Disord
33 34	252	2020; 20:179.
35 36 37	253	3. Musini VM, Lawrence KA, Fortin PM, et al. Blood pressure lowering efficacy of renin
38 39	254	inhibitors for primary hypertension. <i>Cochrane Database Syst Rev</i> 2017; 4:CD007066.
40 41 42	255	4. Liu Y, Chen K, Kou X, et al. Aliskiren and Amlodipine in the Management of Essential
43 44 45	256	Hypertension: Meta-Analysis of Randomized Controlled Trials. PLoS ONE 2013; 8: e70111
46 47	257	5. Miyoshi T, Murakami T, Sakuragi S, et al. Comparable effect of aliskiren or a diuretic
48 49 50	258	added on an angiotensin II receptor blocker on augmentation index in hypertension: a
51 52 53	259	multicentre, prospective, randomised study. Open Heart 2017;4:e000591.
53 54 55	260	6. Abdel Kawy HS. Aliskiren and valsartan in combination is a promising therapy for
56 57 58 59 60	261	hypertensive renal injury in rats. <i>Clin Exp Hypertens</i> 2018; 40:560-8.

7. Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370: 221-9. 8. Littlejohn TW 3rd, Trenkwalder P, Hollanders G, et al. Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. Curr Med Res Opin 2009; 25:951-9. 9. Liu Y, Yan R, Song A, et al. Aliskiren/amlodipine vs. aliskiren/hydrochlorothiazide in hypertension: indirect meta-analysis of trials comparing the two combinations vs. monotherapy. Am J Hypertens 2014; 27:268-78. 10. Zhang JT, Chen KP, Guan T, et al. Effect of aliskiren on cardiovascular outcomes in patients with prehypertension: a meta-analysis of randomized controlled trials. Drug Des Devel Ther 2015;9:1963-71. 11. Aromataris E, Fernandez R, Godfrey CM, et al. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. Int J *Evid Based Healthc* 2015; 13:132-40. 12. Aromataris E, Fernandez RS, Godfrey C, et al. Methodology for JBI Umbrella Reviews. The Joanna Briggs Institute; 2014. 13. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1. 14. Gross A, Schirm S, Scholz M. Ycasd - a tool for capturing and scaling data from graphical representations. BMC Bioinformatics 2014; 15:219.

1 2								
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34	283	15. Shea BJ, Reeves BC, Wells G, et al. AMSTAR2: a critical appraisal tool for systematic						
	284	reviews that include randomised or non-randomised studies of healthcare interventions, or						
	285	both. BMJ 2017; 358:1-8.						
	286	16. Poole R, Kennedy OJ, Roderick P, et al. Coffee consumption and health: umbrella review						
	287	of meta-analyses of multiple health outcomes. BMJ 2017; 359:j5024-18.						
	288	17. Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of						
	289	Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from						
	290	www.training.cochrane.org/handbook.						
	291	18. Pieper D, Antoine S-L, Mathes T, et al. Systematic review finds overlapping reviews						
	292	were not mentioned in every other overview. J Clin Epidemiol 2014; 67:368-75.						
	293	19. Ioannidis J. Next-generation systematic reviews: prospective meta-analysis,						
	294	individual-level data, networks and umbrella reviews. Br J Sports Med 2017; 51:1456-8.						
35 36	295							
37 38 39	296							
40 41	297							
42 43 44	298							
45 46 47	299							
48 49	300							
50 51 52	301							
53 54	302							
55 56 57	303							
58 59 60	304							
00		16						

1 2			
2 3 4 5 6	305	Figure 1	Flow diagram of study selection process
5 6 7			
7 8			
9 10			
11 12			
13 14			
15 16			
17 18			
19 20			
21 22			
23 24			
25 26			
27 28			
29 30			
31 32			
33 34			
35 36			
37 38			
39 40			
41			
42 43 44			
45			
46 47 48			
48 49			
50 51			
52 53			
54 55			
56 57			
58 59			
60			



Supplementary 1

Search Pubmed

- #1 "aliskiren"[Supplementary Concept]
- #2 "Rasilez"[Title/Abstract]
- #3 "tekturna"[Title/Abstract]
 - #4 "spp100"[Title/Abstract]
- #5 "renin angiotensin inhibition"[Title/Abstract]
- #6 "direct renin inhibitor"[Title/Abstract]
- #7 "aliskiren"[Title/Abstract]
- #8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7
- Filters: Meta-Analysis, Systematic Review